Decitabine is a nucleoside metabolic inhibitor approved in the United States and indicated for the treatment of adult patients with myelodysplastic syndromes that targets DNA methyltransferase (DNMT) [32,33]. This evidence concerns the gene DNMT1 and myelodysplastic syndrome.